{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:15:58Z","timestamp":1772460958928,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jneuroim.2025.578558","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:06:34Z","timestamp":1739837194000},"page":"578558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series"],"prefix":"10.1016","volume":"401","author":[{"given":"Dingxian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578558_bb0005","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"A","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0010","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0015","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bcp.2015.06.024","article-title":"Activation of endplate nicotinic acetylcholine receptors by agonists","volume":"97","author":"Auerbach","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16098","article-title":"Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study","volume":"31","author":"Bril","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","article-title":"The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice","volume":"1274","author":"Burns","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0035","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1113\/JP277819","article-title":"Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line","volume":"597","author":"Cetin","year":"2019","journal-title":"J. Physiol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-024-07728-w","article-title":"Clinical characteristics and therapeutic effect of myasthenia gravis coexisting with thyroid eye disease","author":"Chen","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0045","first-page":"257","article-title":"Treatment of ocular myasthenia gravis","volume":"7","author":"Cornblath","year":"2018","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0050","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","article-title":"Recommendations for the management of myasthenia gravis in Belgium","volume":"124","author":"De Bleecker","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0055","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nmd.2019.03.009","article-title":"A review of the histopathological findings in myasthenia gravis: clues to the pathogenesis of treatment-resistance in extraocular muscles","volume":"29","author":"Europa","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0065","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0070","article-title":"\u201cMinimal symptom expression\u201d in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"J","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0075","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Jf","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578558_bb0085","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0090","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41574-024-01016-5","article-title":"Graves disease: latest understanding of pathogenesis and treatment options","volume":"20","author":"Lanzolla","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0095","first-page":"7","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton Myasthenic syndrome: an overview","volume":"76","author":"Murai","year":"2024","journal-title":"Brain Nerve"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0079-6123(05)51002-1","article-title":"Biological organization of the extraocular muscles","volume":"151","author":"Spencer","year":"2006","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/nyas.13503","article-title":"The Association of British Neurologists\u2019 myasthenia gravis guidelines","volume":"1412","author":"Sussman","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2025.578558_bb0125","doi-asserted-by":"crossref","first-page":"e1426","DOI":"10.1212\/WNL.0000000000010209","article-title":"Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis","volume":"95","author":"Tomschik","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s13311-022-01335-3","article-title":"Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis","volume":"20","author":"Uzawa","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0140","article-title":"Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker","volume":"12","author":"Z","year":"2023","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/mus.27517","article-title":"Differences in immunophenotypes between myasthenia gravis patients with and without thyroid antibodies","volume":"65","author":"Zhang","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2025.578558_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-024-03025-z","article-title":"Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study","volume":"19","author":"Zhang","year":"2024","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T05:00:06Z","timestamp":1741669206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"alternative-id":["S0165572825000384"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578558","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578558"}}